GSK’s RSV Vaccine Arexvy Gets Positive CHMP Opinion For Adults Aged 50-59 At Increased Risk
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – GSK plc (GSK, GSK.L) announced Monday that its Respiratory Syncytial Virus or RSV vaccine, Arexvy, has received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use or CHMP for adults aged 50-59 at increased risk for RSV
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")
:max_bytes(150000):strip_icc():format(jpeg)/business-team-investment-entrepreneur-trading-discussing-and-analysis-graph-stock-market-trading-stock-chart-concept-1089940388-acef8549576a4d918cb157c6c88ec8a1.jpg "Introduction to Phantom Stocks and SARs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-991180154-aad62bea33e2473a808a24eb81b8e068.jpg "How the Minimum Wage Impacts Unemployment")
